project id: TCGA-BLCA; case submitter id: TCGA-XF-A9T5; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.85; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.89; rna integrity number: 8.8; age at index: 78; days to birth: -28578; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Alive; year of birth: 1930; age at diagnosis: 28578; ajcc pathologic m: MX; ajcc pathologic n: N1; ajcc pathologic stage: Stage IV; ajcc pathologic t: T3a; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 2027.0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: Not Reported; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; year of diagnosis: 2008; treatment or therapy: yes; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 2105; days to sample procurement: 0; initial weight: 1050.0; portion submitter id: TCGA-XF-A9T5-01A-11; percent lymphocyte infiltration: 3.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 10.0; percent stromal cells: 0.0; percent tumor cells: 90.0; percent tumor nuclei: 75.0;